Your session is about to expire
← Back to Search
Secukinumab for Nail Psoriasis
Study Summary
This trial will study the effectiveness of secukinumab, an FDA-approved drug, in treating nail psoriasis.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have used IL-17 inhibitors before, but other treatments are okay.I have a history of psoriatic arthritis but it's not active now.I have or had skin psoriasis diagnosed by a dermatologist.I am between 18 and 85 years old.I do not have a fungal nail infection on my fingernails.I have psoriasis affecting 4 or more of my fingernails.I have inflammatory bowel disease.I currently have an infection.You have metal implants or other issues that make it unsafe for you to have an MRI.
- Group 1: Open Label
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you please explain what Secukinumab Auto-Injector is typically prescribed for?
"Secukinumab Auto-Injector is typically administered to treat ankylosing spondylitis. However, it has also been found to be beneficial for patients suffering from psoriatic arthritis, enthesitis related arthritis (ERA), and debilitating plaque psoriasis."
Who meets the criteria for participating in this research initiative?
"This trial seeks 40 participants with psoriasis aged 18-85. To qualify, one must have active psoriatic nail disease (minimum of 4 fingernails or a NAPSI score over 20) and either current skin psoriasis without minimum PASI/BSA criteria or documented past skin psoriasis by a dermatologist."
Has Secukinumab Auto-Injector been subject to any prior analyses?
"Currently, 27 research trials are being conducted for Secukinumab Auto-Injector; 13 of those studies have reached Phase 3. While the majority take place in Brest and Buenos Aires, there is a total of 1040 sites running investigations on this treatment."
How many individuals are contibuting to this clinical experiment?
"Currently, this clinical trial has finished recruiting participants. The study was first posted on February 7th 2022 and the information was most recently updated on February 11th 2022. If you are pursuing other studies, 167 trials involving psoriasis patients and 27 trials regarding Secukinumab Auto-Injectors are actively looking for candidates right now."
Is there still capacity for participants in this medical experiment?
"Per the clinicaltrials.gov database, this medical study is no longer recruiting individuals for participation; it was first posted on February 7th 2022 and last modified on February 11th 2022. However, 194 other trials are still actively enrolling patients at present."
Has Secukinumab Auto-Injector been given regulatory approval by the FDA?
"Secukinumab Auto-Injector has been approved for clinical use, resulting in its safety index of 3."
Is the age criterion of 55 years or older necessary to qualify for this clinical experiment?
"According to the trial's eligibility conditions, prospective participants must be at least 18 years old and no older than 85."
Share this study with friends
Copy Link
Messenger